Drug intelligence / Profile preview

68Ga-CTR-FAPI

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-CTR-FAPI is a radiopharmaceutical used for positron emission tomography/computed tomography (PET/CT) imaging in oncology. It is a gallium 68-labeled fibroblast activation protein inhibitor (FAPI) that targets the fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts within the tumor stroma. The CTR modification refers to a covalent targeted radioligand design, aiming to improve detection sensitivity and diagnostic accuracy over standard FAPIs. In clinical studies, [68Ga]Ga-CTR-FAPI PET/CT has demonstrated superior detection rates and diagnostic accuracy compared with [18F]FDG PET/CT, particularly in medullary thyroid carcinoma and other malignancies. Its mechanism of action involves binding to FAP on activated fibroblasts, enabling precise visualization of primary tumors and metastases for improved disease management[6][9].

Other names: 68Ga-CTR-FAPI[68Ga]Ga-CTR-FAPI

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 68Ga-CTR-FAPI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-CTR-FAPI.

Explore the full profile